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Background: The role of hyperuricemia in disease progression of autosomal dominant polycystic kidney disease
(ADPKD) has not been defined well. We investigated the association of serum uric acid (sUA) with renal function
and the effect of hypouricemic treatment on the rate of renal function decline.
Methods: This is a single-center, retrospective, observational cohort study. A total of 365 patients with ADPKD who
had estimated glomerular filtration rate (eGFR)≥ 15 mL/min/1.73 m2 and who were followed up for > 1 year were
included in our analysis. Hyperuricemia was defined by a sUA level of≥ 7.0 mg/dL in male and≥ 6.0 mg/dL in
female or when hypouricemic medications were prescribed.
Results: Hyperuricemia was associated with reduced initial eGFR, independent of age, sex, hypertension,
albuminuria, and total kidney volume. During a median follow-up period of over 6 years, patients with hyperuricemia
showed a faster annual decline in eGFR (−6.3% per year vs. −0.9% per year, p = 0.008). However, after adjusting for
age, sex, hypertension and initial eGFR, sUA was no longer associated with either annual eGFR decline or the
development of ESRD. Among 53 patients who received hypouricemic treatment, the annual eGFR decline
appeared to be attenuated after hypouricemic treatment (pretreatment vs. posttreatment: −5.3 ± 8. 2 vs. 0.2 ± 6.2
mL/min/1.73 m2 per year, p = 0.001 by Wilcoxon signed-rank test).
Conclusions: Although hyperuricemia was associated with reduced eGFR, it was not an independent factor for renal
progression in ADPKD. However, the correction of hyperuricemia may attenuate renal function decline in some patients
with mild renal insufficiency.
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Uric acid has been regarded as a marker rather than a
risk factor for the development of chronic kidney disease
(CKD) because a low glomerular filtration rate (GFR)
induces elevation of serum uric acid (sUA) level despite
compensatory increases in urinary and gastrointestinal
urate excretions. However, recent studies suggested an
independent role of uric acid in the development of
CKD. For instance, hyperuricemia is shown to be associ-
ated with an increased risk of CKD in large cohort* Correspondence: ondahl@eulji.ac.kr; curie@snu.ac.kr
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unless otherwise stated.studies such as the Atherosclerosis Risk in Communities
and the Cardiovascular Health Study [1] and the Vienna
Health Screening Project [2]. Moreover, hyperuricemia
has been reported to be associated with the development
of end-stage renal disease (ESRD) [3,4]. However, the
pathogenic role of hyperuricemia in the progression of
CKD is still controversial. Hyperuricemia has been re-
ported as a risk factor for renal progression in IgA ne-
phropathy [5], whereas sUA level was not associated
with disease progression or kidney failure in general
CKD population [6,7].
Association between autosomal dominant polycystic
kidney disease (ADPKD) and hyperuricemia was first de-
scribed by Rivera et al. [8]. ADPKD is frequently associ-
ated with hyperuricemia and gout [9], although fractional. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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groups of different etiologies [10,11]. Recent retrospect-
ive studies reported the association of high sUA levels
with early-onset hypertension, large kidney volume, and
increased risk of ESRD [12] or progression of renal dys-
function [13]. Considering that hyperuricemia can be a
possible correctable risk factor for ADPKD progression,
we postulated that 1) hyperuricemia is associated with
concurrent renal function, 2) hyperuricemia contributes
independently to deterioration of renal function, 3) and
the correction of hyperuricemia attenuates renal func-
tion decline in ADPKD.
Subjects and methods
Study subjects
A total of 612 patients were screened at the ADPKD
clinic in Seoul National University Hospital. ADPKD
was diagnosed according to the unified criteria proposed
by Pei et al. [14]. We selected 365 patients aged > 18
years with an estimated GFR (eGFR) of > 15 mL/min/
1.73 m2 at the initial evaluation and who were followed
up for > 1 year. Patients with certain conditions that can
independently influence renal function such as diabetes
[15], pregnancy, or malignancy were excluded from the
analysis. The data were collected retrospectively from
each patient between August 1999 and March 2012.
The patients underwent a standardized evaluation in-
cluding detailed family history, renal function, and
computed tomography (CT) scan, which was obtained
using a multidetector CT scanner (Somatom Sensation
16, Siemens; LightSpeed Ultra 8, GE; Brilliance CT 64,
Philips; Somatom Definition, Siemens). The following
clinical data and information were collected every
3–6 months: baseline epidemiologic profiles (age, sex,
and body weight), medical history including diabetes,
hypertension, and gout, medication history including
antihypertensive medications and hypouricemic agents,
blood pressure, and laboratory results (serum creatin-
ine (sCr), sUA, hemoglobin, serum albumin levels, and
urine dipstick). The CT scan was performed every
2 years and total kidney volume (TKV) was calculated
using the modified ellipsoid method [16]. This study
was approved by the Institutional Review Board of
Seoul National University Hospital (H-1002-028-309).
Informed consent was obtained from the subjects in
accordance with the Declaration of Helsinki.
Evaluation of renal function and hypertension
The sCr was measured at 3- or 6-month interval using
the Jaffe method by Hitachi 7600 and Toshiba-200FR,
which was calculated to Isotope Dilution Mass Spec-
trometry (IDMS)-traceable sCr. The Chronic Kidney
Disease Epidemiology collaboration (CKD-EPI) formula
was used to calculate eGFR. Delta eGFR (ΔeGFR/year)was calculated using the equation (recent eGFR − eGFR
at initial visit)/follow-up duration (years). The CKD
stage was classified according to the Kidney Disease
Improving Global Outcomes (KDIGO) guidelines [17].
ESRD was defined by an eGFR of <15 mL/min/1.73 m2
or initiation of renal replacement therapy. Albuminuria
was defined as a stick albumin level of >1+ by urine dip-
stick test. Urine albumin was quantified by the immuno-
turbidimetric assay using Toshiba-120FR. Hypertension
was defined by a systolic blood pressure of >140 mmHg,
diastolic blood pressure of >90 mmHg, or current use of
antihypertensive medication.
Uric acid measurement and hyperuricemia management
The sUA level was determined using the uricase method
(Hitachi 7600 and Toshiba-200FR). Hyperuricemia
was defined by a sUA level of ≥ 7.0 mg/dL in males
and ≥ 6.0 mg/dL in females or when patients have received
hypouricemic treatment. Hypouricemic medications were
prescribed in patients with gout, a history of uric acid
stones, or persistent elevation of sUA level of > 8.0 mg/dL
that was not controlled by dietary modification in 2
successive visits.
Statistical analyses
Continuous variables were expressed as mean ± standard
deviation. Student t -test was used to compare the con-
tinuous variables between the groups. Linear regression
analysis was used to find the association between sUA
and clinical variables. Cox proportional hazard model
was used to compare renal survival between groups.
Wilcoxon signed-rank test was used to evaluate the
effect of hypouricemic medication on the rate of renal
progression before and after the start of medication. P <
0.05 was considered statistically significant. All the stat-
istical analyses were performed using SPSS version 19.0
(SPSS Inc., Chicago, IL).
Results
Baseline clinical characteristics according to the presence
of hyperuricemia
The clinical characteristics of 365 patients on initial
evaluation are summarized in Table 1. They were divided
into normouricemic (Group A, n = 278) and hyperurice-
mic (Group B, n = 87) groups. In Group B, 12 patients
(3.3%) underwent hypouricemic treatment. The preva-
lence of hyperuricemia increased according to CKD
stage as follows: 6.3% (6/95) in stage 1, 15.2% (28/184)
in stage 2, 52.4% (33/63) in stage 3, and 87.0% (20/23) in
stage 4.
When compared with those in Group A, the patients in
Group B were slightly older (47.1 ± 13.2 vs. 42.4 ± 11.3 years,
p = 0.003), had higher prevalence of hypertension (81.6% vs.
66.9%, p = 0.004), showed male predominance (70.1% vs.








Male (%) 183 (50.1%) 122 (43.9%) 61 (70.1%) < 0.001
Age (yrs) 43.5 ± 11.9 42.4 ± 11.3 47.1 ± 13.2 0.003
18-39 159 (43.6%) 128 (46.0%) 31 (35.6%)
40-59 177 (48.5%) 133 (47.8%) 44 (50.6%)
≥ 60 29 (7.9%) 17 (6.1%) 12 (13.8%)
Follow up time (months) 73.5 ± 43.4 76.2 ± 43.5 64.7 ± 42.1 0.031
Hypertension (%) 257 (70.4%) 186 (66.9%) 71 (81.6%) 0.004
Systolic BP (mmHg) 136.4 ± 19.9 136.4 ± 20.3 136.3 ± 18.8 0.967
Diastolic BP (mmHg) 85.6 ± 13.9 86.1 ± 14.2 83.6 ± 12.8 0.190
Urinary stone (%) 96 (26.3%) 71 (25.5%) 25 (28.7%) 0.556
sUA (mg/dL) 5.51 ± 1.71 4.80 ± 1.11 7.76 ± 1.26 < 0.001
sCr (mg/dL) 1.17 ± 0.48 1.01 ± 0.23 1.67 ± 0.69 < 0.001
eGFR (ml/min/1.73 m2) 75.1 ± 24.1 81.6 ± 19.3 54.5 ± 26.3 < 0.001
CKD stage < 0.001
Stage 1 95 (26.0%) 53 (19.1%) 6 (6.9%)
Stage 2 184 (50.4%) 189 (68.0%) 28 (32.2%)
Stage 3 63 (17.3%) 35 (12.6%) 33 (37.9%)
Stage 4 23 (6.3%) 1 (0.4%) 20 (23.0%)
Urine pH 6.03 ± 0.73 6.13 ± 0.73 5.74 ± 0.66 < 0.001
Dipstick albumin 0.017
None to 1+ 342 (93.7%) 266 (95.7%) 76 (87.4%)
> 1+ 23 (6.3%) 12 (4.3%) 11 (12.6%)
TKV (mL) 1,524 ± 1,171 1,416 ± 1,050 1,963 ± 1,500 0.013
Losartan (%) 58 (15.9%) 50 (18.0%) 8 (9.2%) 0.025
Diuretic (%) 36 (9.9%) 27 (9.7%) 9 (10.3%) 0.863
*Group A : sUA < 7.0 mg/dL (Male) or sUA < 6.0 mg/dL (Female), †Group B: sUA ≥ 7.0 mg/dL (Male) or sUA ≥ 6.0 mg/dL (Female) or on hypouricemic medication.
BP, blood pressure; sUA, serum uric acid; sCr, serum creatinine; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; TKV, total kidney volume.
Han et al. BMC Nephrology 2014, 15:63 Page 3 of 8
http://www.biomedcentral.com/1471-2369/15/6343.5%, p < 0.001), and had shorter follow-up duration
(64.7 ± 42.1 vs. 76.2 ± 43.5 months, p = 0.031). Group B
had higher sCr levels (1.67 ± 0.69 vs. 1.01 ± 0.23 mg/dL,
p < 0.001) and lower eGFR (54.5 ± 26.3 vs. 81.6 ± 19.3
mL/min/1.73 m2, p < 0.001) compared to Group A.
Hyperuricemia was negatively correlated with initial eGFR
Associations between sUA and sCr levels, eGFR, TKV, and
albumin to creatinine ratio (ACR) were analysed (Figure 1).
The sUA level was positively correlated with sCr level
(R2 = 0.370, p < 0.001), ACR (R2 = 0.011, p = 0.111) and
TKV (R2 = 0.045, p < 0.001) but negatively correlated with
eGFR (R2 = 0.202, p < 0.001). Simple linear regression
analysis in 353 patients without hypouricemic treatments
at the initial evaluation revealed that age, albuminuria,
TKV, and sUA level were correlated with reduced initial
eGFR. After adjustment for age, male sex, blood pressure,
albuminuria, and TKV, sUA levels still remained a signifi-
cant factor (β = −5.117, p < 0.001; Table 2).Hyperuricemia was not independently associated with
annual eGFR decline and ESRD progression
Among 365 patients, 42 patients (11.5%; 20 in Group A
and 22 in Group B) progressed to ESRD during the
follow-up (mean duration, 73.5 ± 43.4 months). When
evaluating the deterioration of eGFR, we examined 296
patients not taking hypouricemic medication (255 patients
from Group A and 41 patients from Group B) to exclude
the influence of hypouricemic agents (Table 3). The mean
sUA level was 4.69 ± 1.08 mg/dL in normouricemic Group
A and 7.61 ± 0.95 mg/dL in Group B (p < 0.001), indicating
a difference of 2.9 mg/dL. Progression to ESRD oc-
curred in 14 (34.1%) out of 41 patients in Group B and
14 (5.4%) out of 255 patients in Group A (p < 0.001).
Group B showed a faster annual decline in eGFR
(ΔeGFR/year) than Group A in absolute (−1.87 ± 3.30
vs. −0.29 ± 4.22 mL/min/1.73 m2 per year, p = 0.026)
and relative values (−6.23% ± 9.84% vs. −0.72% ± 6.03%
per year, p = 0.001).
Figure 1 The association of serum uric acid level with serum creatinine, eGFR, albuminuria and TKV. Relationship between serum uric
acid (sUA) level with serum creatinine (sCr) (R2 = 0.370, p < 0.001), eGFR (R2 = 0.202, p < 0.001), Log albumin-to-creatinine ratio (ACR) (R2 = 0.011,
p = 0.111) and LogTKV (R2 = 0.045, p < 0.001) in ADPKD patients. The sCr and eGFR was measured in 365 patients, ACR in 230 patients and TKV
in 278 patients. eGFR, estimated glomerular filtration rate; TKV, total kidney volume; ADPKD, autosomal dominant polycystic kidney disease.
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the factors influencing ΔeGFR/year. In univariate ana-
lysis, age, hypertension, initial eGFR, and sUA level
were significantly associated with ΔeGFR/year. How-
ever, after adjusting for age, sex, blood pressure, and ini-
tial eGFR, neither sUA level nor hyperuricemia was
significantly associated with ΔeGFR/year (Table 4). In
the same manner, multivariate Cox regression analysisTable 2 Factors associated with eGFR in ADPKD patients*
Univariate
Beta ± SE p
Age (yr) −1.208 ± 0.087 <
Female (vs. male) −2.714 ± 2.520 0
Mean BP (mm Hg) −0.229 ± 0.089 0
sUA (mg/dL) −6.282 ± 0.666 <
Albuminuria −14.687 ± 5.160 0
TKV (mL)† −19.524 ± 4.060 <
*353 patients without hypouricemic medication. †transformed in logarithmic scale. e
polycystic kidney disease; SE, standard error; BP, blood pressure; sUA, serum uric acshowed that hyperuricemia was not an independent risk
factor for ESRD (Table 5).
Correction of hyperuricemia may attenuate renal function
decline
Although we were not able to show the independent
association of sUA level with renal progression in ADPKD
patients who were not taking hypouricemic agents, we didMultivariate
-value Beta ± SE p-value
0.001 −0.986 ± 0.086 < 0.001
.282 −9.217 ± 2.224 < 0.001
.010 0.043 ± 0.073 0.558
0.001 −5.117 ± 0.666 < 0.001
.005 −4.956 ± 3.890 0.204
0.001 −12.782 ± 3.245 < 0.001
GFR, estimated glomerular filtration rate; ADPKD, autosomal dominant
id; TKV, total kidney volume.
Table 3 Annual eGFR decline (ΔeGFR) in ADPKD patients






Mean sUA level (mg/dL) 4.69 ± 1.08 7.61 ± 0.95 < 0.001
F/U time (months) 73.0 ± 42.2 62.0 ± 46.8 0.134
Initial eGFR (mL/min/1.73 m2) 82.0 ± 19.6 52.2 ± 27.4 < 0.001
Final eGFR (mL/min/1.73 m2) 75.6 ± 27.9 48.3 ± 31.7 < 0.001
ΔeGFR (mL/min/1.73 m2/yr) −0.29 ± 4.22 −1.87 ± 3.30 0.026
ΔeGFR (%/yr) −0.72 ± 6.03 −6.23 ± 9.84 0.001
ESRD progression, n (%) 14 (5.4%) 14 (34.1%) < 0.001
*A total of 296 patients without hypouricemic medications were included in
the analysis. †Group A: sUA < 7.0 mg/dL (Male) or < 6.0 mg/dL (Female),
‡Group B: sUA ≥ 7.0 mg/dL (Male) or ≥ 6.0 mg/dL. sUA, serum uric acid; ADPKD,
autosomal dominant polycystic kidney disease; F/U, follow-up; eGFR, estimated
glomerular filtration rate; ESRD, end-stage renal disease.
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gate the effect of hypouricemic treatment on eGFR.
Among 57 patients newly starting hypouricemic treatment
during follow-up period, 53 patients had follow-up period
more than 1 year of pre- and post-treatment. Serum UA
and eGFR were measured every 3 months. The slopes of
the annual change in eGFR before and after hypouricemic
treatment were analyzed in 53 patients receiving either
allopurinol (n = 12) or benzbromarone (n = 41) more than
a year.
Among them, 13 patients were included in CKD stage
1 or 2, 19 in CKD stage 3a, 11 in CKD stage 3b, and 10
in CKD stage 4 before treatment initiation. Mean sUA
was 8.70 ± 0.78 mg/dL and mean eGFR was 47.9 ± 20.3
mL/min/1.73 m2 at the time of hypouricemic treatment
initiation. The change in sUA and eGFR before and after
1 year of treatment initiation was analyzed (Table 6).
After the hypouricemic treatment, the annual decline
of renal function (ΔGFR/year) slowed from −5.3 ± 8.2
to 0.2 ± 6.2 mL/min/1.73 m2 per year (Wilcoxon signed-
rank test, p = 0.001). Further analysis showed that cor-
rection of hyperuricemia may attenuate renal function
decline in early CKD stages (1 ~ 3a) whereas it may notTable 4 Factors affecting annual eGFR decline (ΔeGFR) in pat
Univariate
Beta ± SE
Age (yr) −0.067 ± 0.020
Female 0.369 ± 0.491
Mean BP (mm Hg) −0.065 ± 0.018
History of stone 0.260 ± 0.377
sUA (mg/dL) −0.330 ± 0.165
Initial eGFR (mL/min/1.73 m2) 0.036 ± 0.010
eGFR, estimated glomerular filtration rate; ADPKD, autosomal dominant polycystic kattenuate renal function decline in advanced CKD
stages (3b ~ 4). Serial changes in sUA and eGFR are
presented in Figure 2 and Additional file 1: Table S1.
There was no difference between allopurinol and benz-
bromarone group (data not shown). However, signifi-
cant changes in systolic blood pressure were also
observed after hypouricemic treatment (Additional file
1: Table S2). Because lowering blood pressure itself
and change of anti-hypertensive medication (32.1%
during the observation period), especially of renin-
angiotensin system blockers may affect eGFR, the
effect of blood pressure on eGFR was examined by
using generalized estimating equation, showing that no
significant effect over 2-year observation period (data
not shown). In summary, blood pressure changes did
not significantly influence eGFR changes after hypouri-
cemic treatment.Discussion
In our retrospective cohort study, we demonstrated
that sUA level is associated with renal function in
ADPKD. However, we were not able to show that
hyperuricemia independently contributes to the renal
progression.
In our study, sUA level was associated with concurrent
eGFR, independent of age, sex, albuminuria, and TKV.
This result is consistent with those from previous studies
reporting that hyperuricemia is associated with early-
onset hypertension, TKV, and increased risk of ESRD
[12]. Hyperuricemia also showed negative correlation
with ΔeGFR/year. However, after adjusting age, sex,
blood pressure, and initial eGFR, the influence of hyper-
uricemia was not statistically significant. This result may
be partly explained by the small difference in sUA level
between patients with and without hyperuricemia be-
cause we excluded high-risk patients with hyperuricemia
who were already being treated. Moreover, the follow-up
duration was relatively short. The median follow-up dur-
ation was only 73.5 months, and 41.6% of the patients
were followed up for <5 years.ients with ADPKD
Multivariate
p-value Beta ± SE p-value
0.001 −0.071 ± 0.034 0.036
0.453 0.775 ± 0.731 0.290
0.001 −0.056 ± 0.019 0.003
0.491 - -
0.047 −0.212 ± 0.275 0.443
0.001 −0.001 ± 0.020 0.971
idney disease; BP, blood pressure; sUA, serum uric acid; SE, standard error.
Table 5 Multivariate cox regression for development of
end-stage renal disease
Hazard ratio 95% CI p-value
Age (year) 0.931 0.864, 1.003 0.060
Female 3.664 0.011, 1239.509 0.662
Initial eGFR (mL/min/1.73 m2) 0.720 0.620, 0.836 < 0.001
Mean BP (mm Hg) 1.023 0.978, 1.070 0.331
Hyperuricemia (Group B vs. A) 3.082 0.008, 1259.413 0.714
Group A: sUA <7.0 mg/dL, Group B: sUA ≥7.0 mg/dL. CI, confidence interval;
eGFR, estimated glomerular filtration rate; BP, blood pressure.
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hyperuricemia on renal progression, we examined the
effect of hypouricemic medication on the slope of annual
eGFR change. Correction of hyperuricemia appeared to
attenuate ΔeGFR/year, especially for the patients in
early CKD stages (1~3a), suggesting that hyperuri-
cemia may influence renal function deterioration in
some patients. Although our result is limited by small
number of patients and short observation time, this is
consistent with the previous finding that allopurinol
therapy preserved sCr level and lowered the risk of
renal progression in hyperuricemic patients with mild
to moderate CKD [18,19]. On the contrary, hypourice-
mic treatment had no effect on preserving eGFR in pa-
tients with CKD stage 3b to 4. This lack of effect may
be related to the lower efficacy of uricosuric agents (e.g.
benzbromarone) in the advance kidney failure. Mean
sUA level decreased from 8.9 ± 0.9 mg/dL to 5.7 ± 1.4
mg/dL in stage 1-3a group, whereas from 8.8 ± 0.6
mg/dL to 7.0 ± 0.9 mg/dL in stage 3b-4 group. The ef-
fect of hypouricemic agents for renal function preser-
vation in advanced CKD stage should be evaluated withTable 6 Annual eGFR change (ΔeGFR) before and after hypou
CKD stage PreTx (1 yr)
Total (n = 53)
sUA (mg/dL) 7.88 ± 1.09
eGFR (mL/min/1.73 m2) 53.2 ± 20.3
ΔeGFR (mL/min/1.73 m2/yr) −5.3 ± 8.2
Stage 1-3a (n = 32)
sUA (mg/dL) 8.06 ± 1.15
eGFR (mL/min/1.73 m2) 64.8 ± 16.3
ΔeGFR (mL/min/1.73 m2/yr) −4.5 ± 9.4
Stage 3b-4 (n = 21)
sUA (mg/dL) 7.62 ± 0.97
eGFR (mL/min/1.73 m2) 35.6 ± 10.9
ΔeGFR (mL/min/1.73 m2/yr) −6.6 ± 5.7
*Wilcoxon signed-rank test. eGFR, estimated glomerular filtration rate; CKD, chronicmore potent hypouricemic agents such as febuxostat in
long-term prospective studies.
Several mechanisms were proposed to explain renal
dysfunction by hyperuricemia. First, association be-
tween increased sUA level and cardiovascular disease
has been reported [20]. In our study, no difference
in cardiovascular event was observed between the
normouricemic and hyperuricemic groups (data not
shown). However, the possibility of hyperuricemia
causing renal function decline through cardiovascular
events cannot be excluded because of the small sample
size and short-term follow-up [21]. Second, hyperurice-
mia may induce direct renal injury through the activa-
tion of the renin-angiotensin aldosterone system
(RAS). Renal cyst enlargement in ADPKD is known to
be associated with stimulation of the circulating and
intrarenal RAS [22]. Helal et al. [12] speculated that
endothelial dysfunction, which is a well-known charac-
teristic of ADPKD [23], and activation of RAS induced
by hyperuricemia would contribute to the progression
of ESRD in ADPKD. Endothelial dysfunction and early-
onset hypertension are important prognostic factors for
the deterioration of renal function in ADPKD [24]. In
addition, soluble uric acid might activate inflammatory
pathways such as tumor necrosis factor alpha (TNF-α)
and chemokines [25] and C-reactive protein [26],
possibly leading to interstitial fibrosis. In CKD patients,
association between hyperuricemia and increased urinary
transforming growth factor beta (TGF-β) was also
reported [27].
The pathogenic role of hyperuricemia in renal progres-
sion needs to be further investigated in regard to urate
handling in ADPKD. In ADPKD, altered tubular mem-
brane transport process might affect renal urate hand-
ling and homeostasis. Compared to general population,ricemic treatment
Initiation of Tx PostTx (1 yr) p-value*
8.70 ± 0.78 6.22 ± 1.40
47.9 ± 20.3 48.1 ± 22.9
0.2 ± 6.2 0.001
8.66 ± 0.90 5.70 ± 1.41
60.3 ± 16.1 62.6 ± 16.4
2.3 ± 5.7 0.001
8.77 ± 0.59 7.03 ± 0.94
29.1 ± 7.2 26.0 ± 10.0
−3.1 ± 5.6 0.465
kidney disease; Tx, treatment; sUA, serum uric acid.
Figure 2 Serial change in sUA and eGFR before and after hypouricemic treatment. After initiation of hypouricemic treatment, mean sUA
level decreased from 8.7 ± 0.9 to 5.7 ± 1.4 mg/dL in CKD stage 1-3a group, whereas from 8.8 ± 0.6 to 7.0 ± 0.9 mg/dL in CKD stage 3b-4 group.
Mean eGFR level increased from 60.3 ± 16.1 to 62.6 ± 16.4 mL/min/1.73 m2 in CKD stage 1-3a group, whereas eGFR decreased from 29.1 ± 7.2 to
26.0 ± 10.0 mL/min/1.73 m2 in CKD stage 3b-4 group.
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ADPKD. However, previous studies showed inconsistent
data about urate handling in ADPKD [10,11]. We also
performed immunohistochemical staining of four
major urate transporters (URAT1, GLUT9, NPT4, and
OAT3) in 3 ADPKD kidneys and 1 normal control
kidney, which revealed strong expression of all 4 urate
transporters along the compressed proximal tubules
nearby renal cysts [28] (Additional file 2: Figure S1). It
may suggest the possibility of altered urate handling in
ADPKD that may lead to hyperuricemia. However, our
result needs to be validated through functional study in
a large number of samples.
Our study has several limitations. This is a single-
center, retrospective cohort study. Therefore, further
prospective study is warranted to evaluate the causal
relationship between hyperuricemia and renal function
decline. In addition, genetic factor, which is the stron-
gest predictor of renal progression, has not been evalu-
ated in this study. In the analysis of the hyperuricemia
and annual eGFR decline, mixed effects model or gen-
eralized estimating equation model would be best
suited. However, they could not be used due to some
missing data of sUA and eGFR during follow-up period
and the interval of measurement was not regular.
Lastly, we failed to show the independent effect of
hyperuricemia on renal progression.
Conclusions
In conclusion, we failed to show the independent effect
of hyperuricemia on renal progression. Nevertheless,
for the first time, we demonstrated the correction of
hyperuricemia with uric acid lowering agents may
attenuate renal progression in the early CKD stages
suggesting that treatment of hyperuricemia would be
beneficial for some ADPKD patients to preserve renalfunction. Further prospective study is needed to verify
the impact of hyperuricemia control on disease pro-
gression in ADPKD.
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